Want to trade stocks without commission?<\/p>\n

Gain access to over 1000 US stocks for commission-free trading on the R StocksTrader<\/span> platform<\/p>\n <\/div>\n

<\/span><\/a>Novo Nordisk in brief<\/span><\/h2>\n\n\n\n
Established in Denmark in 1923, Novo Nordisk A\/S develops medications for the treatment of diabetes mellitus, haemophilia, growth disorders, obesity, and other diseases. The corporation has subsidiaries in over 80 countries and sells its products in more than 170 countries.<\/p>\n\n\n\n
<\/span><\/a>Rising obesity rates in the US<\/span><\/h2>\n\n\n\n
The World Health Organisation defines<\/a> obesity as a body mass index equal to or greater than 30. According to the Trust for America's Health (TFAH) annual report<\/a> on the obesity crisis, published in September 2022, 41.9% of American adults are obese, and this rate continues to rise across the US. It is projected that by 2023, nearly half of the population of the US (48.9%) will be overweight, with 24.2% suffering from severe obesity. This situation is driving demand for drugs to combat obesity and related diseases.<\/p>\n\n\n\n
<\/span><\/a>Who is Novo Nordisk’s primary competitor in this segment?<\/span><\/h2>\n\n\n\n
As mentioned above, Pfizer Inc. discontinued the development of lotiglipron due to repeated cases of elevated liver enzymes in patients. Investors reacted negatively to this news with Pfizer Inc. stock losing 3.7% on 26 June 2023. By 11 September, the time of writing, the stock value had decreased by 10.5%.<\/p>\n\n\n
<\/rg-instrument><\/div>\n\n\n\n
$\"Pfizer$ <\/a>
Pfizer Inc. stock chart<\/a>*<\/em><\/figcaption><\/figure>\n\n\n\n
Today, Eli Lilly and Company<\/a> (NYSE: LLY) is Novo Nordisk A\/S’s main competitor in the weight loss medication market. The shares<\/a> of both representatives of the pharmaceutical sector are trading<\/a> at historic highs.<\/p>\n\n\n\n
<\/span><\/a>What has fueled the demand for Novo Nordisk’s Wegovy?<\/span><\/h2>\n\n\n\n
Wegovy, a weight loss drug taken once a week as an injection, gained approval from the Food and Drug Administration (FDA) in June 2021.<\/p>\n\n\n\n
It contains semaglutide, which suppresses appetite and boosts metabolism. Clinical trials<\/a> have demonstrated its high efficacy, resulting in a 15% weight reduction when combined with a diet and physical exercise.<\/p>\n\n\n\n
The effectiveness of Wegovy has boosted the demand for the drug in the US and other countries. Additionally, enthusiastic reviews<\/a> on social media contributed to increasing its popularity.<\/p>\n\n\n\n
On 8 August 2023, Novo Nordisk A\/S announced<\/a> positive results from a large-scale clinical trial named SELECT, which investigated the effects of Wegovy on cardiovascular health in obese people. The trial enrolled 17,604 overweight or obese adult patients with established cardiovascular disease.<\/p>\n\n\n\n
The research showed that Wegovy reduced the risk of heart attacks, strokes or death from cardiovascular problems by 20% compared to a placebo. This was the first research to prove that a weight loss drug can prevent serious health complications in obese people.<\/p>\n\n\n\n
On the day the official press release was published, Novo Nordisk A\/S stock added 17.2%, rising to 189.17 USD per unit. It is worth noting that the use of Wegovy not only to combat overweight but also to treat obesity-related diseases could significantly increase order volumes.<\/p>\n\n\n\n
\n
\n
\n
Want to trade with premium conditions?<\/p>\n
Open a Prime account and enjoy fast execution, low commissions, and spreads from 0 pips<\/p>\n <\/div>\n
\n $\"partner-programme\"$ \n <\/div>\n Open a Prime Account<\/a>\n <\/div>\n
\n $\"partner-programme\"$ \n <\/div>\n <\/div>\n\n\n\n
<\/span><\/a>Novo Nordisk ramps up Wegovy production in response to soaring demand<\/span><\/h2>\n\n\n\n
Novo Nordisk A\/S CEO Lars Fruergaard Jorgensen said<\/a> that in terms of Wegovy orders, the company is dealing with almost a billion potential customers worldwide, referring to people with existing or potential overweight problems.<\/p>\n\n\n\n
On 12 June, the company published a press release<\/a>,<\/ins> announcing that Novo Nordisk A\/S is investing 15.9 billion DKK in expanding its manufacturing facilities. The company is concerned that even with this step, it may not be enough to meet the rising demand for Wegovy in the near future.<\/p>\n\n\n\n
To solve the problem of Wegovy shortage in the UK, it was decided<\/a> to make it available through a controlled and limited launch programme. In the US, Novo Nordisk A\/S had previously implemented restrictions<\/a> on the supply of Wegovy initial doses to ensure the continuity of the treatment cycle for existing patients.<\/p>\n\n\n\n
<\/span><\/a>Novo Nordisk strengthens its position in the weight loss market<\/span><\/h2>\n\n\n\n
On 10 August 2023, it was announced<\/a> that Novo Nordisk A\/S is acquiring Inversago Pharma, which is developing the INV-202 drug that suppresses appetite in patients with metabolic syndrome. It has successfully passed the first phase of clinical trials and is currently in phase 2. The deal’s value could reach up to 1.08 billion USD and will depend on whether specific development and launch milestones are achieved.<\/p>\n\n\n\n
This deal could be advantageous for both companies: Novo Nordisk A\/S gains access to the potentially first-in-class obesity treatment, while Inversago Pharma receives financial support and the expertise of the leading player in the diabetes and obesity drug market.<\/p>\n\n\n\n
<\/span><\/a>Novo Nordisk live stock price chart<\/span><\/h2>\n\n\n\n\n